Janpix picks STAT inhibitors for blood cancers

How Janpix’s small molecules are specific for STAT3 and STAT5

Janpix is developing STAT3 and STAT5 inhibitors that could treat hematologic malignancies with greater durability and lower risk of side effects than other inhibitors of the JAK-STAT pathway.

Janpix Inc. in-licensed its family of small molecule scaffolds from the University of Toronto, where Janpix co-founder and CSO Patrick Gunning is a professor of chemistry.

In cancer, STAT proteins are phosphorylated and activated by JAKs and other kinases, causing STAT

Read the full 672 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE